Nepafenac

Drug Profile

Nepafenac

Alternative Names: AL-6515; Ilevro; Nepafenac ophthalmic suspension 0.1% - Alcon; Nevanac

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcon
  • Class Analgesics; Aniline compounds; Anti-inflammatories; Benzeneacetamides; Benzophenones; Eye disorder therapies; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain; Retinal oedema
  • Phase III Diabetic retinopathy

Most Recent Events

  • 08 May 2017 The Scottish Medicines Consortium approves nepafenac for the reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients
  • 15 Dec 2016 Biomarkers information updated
  • 01 May 2015 Alcon Research completes the study 1 phase III trial in Diabetic retinopathy in USA (NCT01853072)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top